Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362661 | 1.00 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22815352 | 1.00 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL22692196 | 0.84 | HCAR2 (0.34) | HCAR2HCAR3GPR84NR1I2 | |
| SCHEMBL18558528 | 0.79 | MAPT (0.32) | HCAR2GPR84NR1I2 | |
| SCHEMBL26775764 | 0.79 | CYP1A2 (0.34) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL19362615 | 0.78 | HPGD (0.32) | HCAR2GPR84NR1I2 | |
| SCHEMBL19362616 | 0.78 | AURKA (0.33) | HCAR2GPR84AURKANR1I2 | |
| SCHEMBL24688350 | 0.75 | HCAR2 (0.38) | HCAR2HCAR3GPR84 | |
| SCHEMBL25934674 | 0.73 | CYP1A2 (0.35) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18558209 | 0.70 | NR1I2 (0.36) | GPR84NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399250-A1 | Pyrimidine Derivatives as Tropomyosin Receptor Kinase A (TRKA) Inhibitors | BIOMED X GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399250-A1 | Pyrimidine Derivatives as Tropomyosin Receptor Kinase A (TRKA) Inhibitors | TPM3, NGF, TK1 | CYP1A2 3497/4885CYP2D6 3866/4885CYP19A1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.